Table 2.
Outcomes at 1, 3, and 5 years.
| Relapse | NRM | DFS | OS | GRFS | CRFS | chronic GVHD | chronic GVHD requiring systemic treatment | ||
|---|---|---|---|---|---|---|---|---|---|
| 1 year | PTCy (n = 44) | 22.7% [11.6–36] | 11.4% [4.1–22.8] | 65.9% [50–77.8] | 79.5% [64.4–88.8] | 56.8% [41–69.9] | 56.8% [41–69.9] | 32.5% [18.5–47.2] | 13.6% [5.4–25.6] |
| ATG (n = 37) | 27% [13.9–42] | 8.1% [2–19.8] | 64.9% [47.3–77.9] | 81.1% [64.4–90.5] | 40.5% [24.9–55.7] | 40.5% [24.9–55.7] | 36.1% [20.7–51.8] | 24.3% [11.9–39.2] | |
| P value (censored at 1 year) | 0.61 | 0.66 | 0.82 | 0.91 | 0.12 | 0.11 | 0.72 | 0.58 | |
| 3 years | PTCy (n = 44) | 27.3% [15–41] | 11.4% [4.1–22.8] | 61.4% [45.4–73.9] | 72.7% [57–83.5] | 47.7% [32.5–61.5] | 47.7% [32.5–61.5] | 32.5% [18.5–47.2] | 18.2% [8.4–30.9] |
| ATG (n = 37) | 32.4% [18–47.7] | 10.8% [3.3–23.3] | 56.8% [39.4–70.8] | 64.9% [47.3–77.9] | 37.8% [22.6–53] | 37.8% [22.6–53] | 41.7% [25.2–57.4] | 27% [13.8–42.1] | |
| 5 years | PTCy (n = 44) | 27.3% [15–41] | 18.6% [7.3–33.8] | 54.2% [36.8–68.6] | 60.3% [42.5–74.2] | 43.2% [28.4–57.1] | 43.2% [28.4–57.1] | 32.5% [18.5–47.2] | 22.7% [11.6–36.1] |
| ATG (n = 37) | 37.6% [20.8–54.4] | 10.8% [3.3–23.3] | 51.6% [33.2–67.2] | 60.5% [42.1–74.7] | 37.8% [22.6–53] | 37.8% [22.6–53] | 41.7% [25.2–57.4] | 27% [13.8–42.1] | |
| p value (entire FU) | 0.52 | 0.57 | 0.77 | 0.94 | 0.39 | 0.37 | 0.44 | 0.58 |
NRM non-relapse mortality, DFS disease-free survival, OS overall survival, GRFS graft-versus-host disease- free, relapse-free survival, CRFS chronic graft-versus-host disease-free, relapse-free survival, GVHD graft-versus-host disease, PTCy post-transplant cyclophosphamide, ATG anti-thymocyte globulin, FU follow-up.